Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that can cause cartilage and bone destruction if left untreated \[[@CR1]\]. Upon confirming a diagnosis of RA, a variety of treatment approaches are typically considered, including non-steroidal anti-inflammatory drugs (NSAIDs), synthetic disease-modifying anti-rheumatic drugs (DMARDs), biologic DMARDs, and glucocorticoids. The use of glucocorticoids has long been a therapeutic option to treat RA, but their long-term administration is often hampered by adverse effects, many of which may be dose dependent. The use of low-dose prednisone therapy results in less joint damage and improved disease control and physical function when combined with other DMARDs as compared to DMARD therapy alone \[[@CR2]\]. Further, the addition of prednisone to DMARD therapy may reduce the need to add biologic therapy or escalate DMARD doses to meet disease target measures \[[@CR2]\].

RA is commonly treated with low-dose immediate-release prednisone (IR-prednisone) in the morning upon awakening. This timing may not optimize control of inflammation and disease symptoms because inflammatory cytokines peak before awakening, typically around 2--4 a.m. \[[@CR3]\]. Administering a delayed-release prednisone (DR-prednisone) tablet at bedtime enables timed delivery of prednisone before and during this circadian peak of inflammatory cytokine release and thereby potentially influences disease symptoms \[[@CR4]\]. IR-prednisone is typically dosed upon awakening after the peak of the inflammatory process in RA. A 12-week, randomized controlled study previously demonstrated that patients treated with concomitant DMARDs and DR-prednisone had a significant reduction in morning stiffness compared with patients treated with DMARD monotherapy \[[@CR5]\]. Another 12-week, randomized trial showed that patients treated with DR-prednisone had significantly reduced morning stiffness compared with those treated with IR-prednisone \[[@CR6]\], and similar improvements were observed in patients who switched from IR- to DR-prednisone in an open-label extension trial \[[@CR7], [@CR8]\]. No previous controlled trial has allowed for prednisone dose adjustments to determine whether efficacy could be maintained at a lower total glucocorticoid dose. The current study was undertaken to assess the effectiveness of switching from conventional IR-prednisone therapy to DR-prednisone in patients with moderately to severely active rheumatoid arthritis in a practice-based setting using standard rheumatoid arthritis patient assessments and permitting dose adjustments.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a 12-week, prospective study (ClinicalTrials.gov: NCT02287610) of patients in the USA at 14 sites (Alabama, Arizona, California, Florida, Georgia, Kentucky, New York, North Carolina, Ohio, Texas) who were aged 18 years or older with moderate to severe rheumatoid arthritis (according to the 2010 American College of Rheumatology and/or European League Against Rheumatism classification criteria), with RA disease activity as defined by disease activity score in 28 joints (DAS28) of ≥3.2 \[calculated with either C-reactive protein (DAS28-CRP) or erythrocyte sedimentation rate (DAS28-ESR)\] and additionally morning stiffness duration of ≥45 min at study entry. To be eligible for study participation, at the time of study entry patients had to be receiving conventional immediate-release prednisone at a dose ≥2.5 mg every morning. Patients subsequently made the decision with their physicians to convert to DR-prednisone (Horizon Pharma USA, Inc., Lake Forest, IL). The choice of DR-prednisone dose was at the physician's discretion, and alterations of the dose during the study were allowed based on individual considerations. Patients were maintained on existing background therapies during the study. Physicians queried patients regarding their actual utilization of DR-prednisone and, as appropriate, other prescription and over-the-counter treatments.

The study protocol was reviewed and approved by an institutional review board. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for inclusion in the study.

Endpoints {#Sec4}
---------

The primary endpoint was mean reduction in morning stiffness severity \[using a 100-mm visual analog scale (VAS)\] from baseline to final follow-up visit. Secondary endpoints included change in duration of morning stiffness (minutes), patient global assessment in disease activity (PGA; 0--10 cm VAS; 0, very well; 10, very poor), physician global assessment in disease activity (PhGA, 0--10 cm VAS; 0, very well; 10, very poor), DAS28-CRP, DAS28-ESR, Clinical Disease Activity Index (CDAI; composite tool; score 0--76), Simple Disease Activity Index (SDAI; composite tool; score 0--86), and routine assessment of patient index data (RAPID3), which includes physical function, pain, and three patient-reported assessments, utilizing a portion of the Multidimensional Health Assessment Questionnaire (MDHAQ). Secondary endpoints also included evaluation of change in the total daily prednisone dose from baseline to final follow-up visit. The changes from baseline in other measurements used in composite tools of CDAI and SDAI, such as tender joint count of 28 joints (TJC28) and swollen joint count of 28 joints (SJC28), were also evaluated.

Primary and secondary endpoints were evaluated in patients with baseline and any follow-up measurements. No pre-defined visits, medical or laboratory tests, procedures, or interventions were required. Rather, all evaluations and procedures were at the discretion of the investigator. As the length of time between baseline and follow-up measurements was not mandated by the study design, the number of patients and length of time on study may have differed within each measurement and cohort examined. A subset of the endpoints was evaluated in the patients receiving DR-prednisone for ≥10 weeks and in patients who were receiving DR-prednisone for ≥10 weeks and had \>60 min of morning stiffness at baseline to match that seen in the previously published controlled trials \[[@CR5], [@CR6], [@CR8], [@CR9]\].

Adverse Events {#Sec5}
--------------

Adverse events (AEs) were defined as any untoward medical occurrence in a patient receiving treatment that did not necessarily have a causal relationship with the treatment; relation to treatment with DR-prednisone was determined by the investigator. A serious AE was defined as any event that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, resulted in a congenital anomaly or birth defect, or was otherwise deemed an important medical event. Evaluation of AEs occurred at three follow-up visits, estimated to occur at 4, 8, and 12 weeks after baseline. AEs and serious AEs were categorized according to the Medical Dictionary for Regulatory Activities (MedDRA), system organ class, and preferred term.

Statistical Analysis {#Sec6}
--------------------

Analyses and tabulations were performed using Microsoft Excel 2010 and SAS^®^. For the primary and most of the secondary endpoints, data are presented as a comparison between results obtained when patients were treated with conventional IR-prednisone (baseline) vs. results obtained when patients were treated with DR-prednisone at follow-up visits. As each patient served as their own control, significance was determined using paired *t* tests; *R* ^2^ coefficients were used for associations.

Results {#Sec7}
=======

Study Population {#Sec8}
----------------

Patients were enrolled into the study between November 2014 and September 2015. Practicing rheumatologists at 14 sites enrolled 75 patients: 11 did not meet eligibility criteria, 3 never received DR-prednisone, and 5 were not included because of lack of follow-up (Fig. [1](#Fig1){ref-type="fig"}). Of the 56 patients who had follow-up data (follow-up population) included in the analysis, 29 patients were receiving therapy for ≥10 weeks and 16 patients were receiving therapy for ≥10 weeks and had \>60 min of baseline morning stiffness. Patient demographics, baseline disease characteristics, and prior and concomitant medications were similar to previous studies (Table [1](#Tab1){ref-type="table"}). In the follow-up population, the mean \[SD\] baseline dose of prednisone was 6.53 mg \[3.73\] (range, 2.5--20 mg).Fig. 1Patient disposition. *Superscript letter* denotes participants who never received the drug who were also categorized as patient choice (2) or lost to follow-up (1). *MS* morning stiffness Table 1Patient demographics and baseline disease characteristicsCharacteristicDelayed-release prednisone (*n* = 56)Age, years, mean (SD)63.05 (12.72)Female, *n* (%)44 (78.57)White, *n* (%)40 (71.43)Height, inches, mean (SD)64.0 (3.97)Weight, lb, mean (SD)174.9 (41.67)Time since RA diagnosis, years, mean (SD)^a^5.09 (5.76)Age at RA diagnosis, years, mean (SD)56.49 (14.69)Baseline prior and concomitant medications, *n* (%) DMARDs47 (83.93) Biologic response modifiers33 (58.93) Analgesics other than NSAIDs21 (37.50) NSAIDs13 (23.21)Baseline DAS28-CRP *n*45 Mean (SD)5.00 (1.10)Baseline DAS28-ESR *n*33 Mean (SD)4.98 (1.28)*DAS28-CRP* disease activity score in 28 joints by C-reactive protein, *DAS28-ESR* disease activity score in 28 joints by erythrocyte sedimentation rate, *DMARD* disease-modifying antirheumatic drug, *NSAIDs* nonsteroidal anti-inflammatory drugs, *RA* rheumatoid arthritis, *SD* standard deviation^a^*n* = 46

Endpoints {#Sec9}
---------

In the follow-up population, patients were receiving DR-prednisone for a mean (SD) of 9.92 (4.47) weeks (range 0.43--18.71 weeks); the average morning stiffness severity and duration at baseline were 56.37 mm and 114.02 min, respectively. Upon switching to DR-prednisone, patients with a follow-up visit had a mean (SD) decrease of 5.16 (27.26) mm in the primary endpoint of morning stiffness severity and 18.90 (77.49) minutes in the secondary endpoint of morning stiffness duration. While the primary endpoint was not statistically significant, comparison of baseline measurements with those at the last follow-up visit revealed significant reductions in the clinically important secondary endpoints of swollen joint count of 28 joints (SJC28; −21.97%), routine assessment of patient index data (RAPID3; −11.95%), physician global assessment (PhGA; −13.73%), and DAS28 by C-reactive protein (DAS28-CRP; −11.93%) (Fig. [2](#Fig2){ref-type="fig"}). Tender joint count of 28 joint (TJC28) scores decreased but were not statistically significant \[mean (SD), 10.97 (8.73) vs. 13.05 (7.75) at baseline; *n* = 39; *p* = 0.07\]. Although the changes in CDAI and SDAI scores were not statistically significant, 24% of patients improved by one category (i.e., high, moderate, or low disease activity or remission) from baseline to final follow-up. Additionally, the prednisone dose decreased by 15% from baseline \[mean (SD), 5.57 (2.32) vs. 6.53 (3.73) mg at baseline; *n* = 56; *p* = 0.05\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2SJC28 (**a**), RAPID3 (**b**), PhGA of disease activity (**c**), and DAS28-CRP (**d**) for patients on DR-prednisone with follow-up. Data are summarized as the mean (standard deviation). *DAS28-CRP* disease activity score in 28 joints by C-reactive protein, *PhGA* physician global assessment, *RAPID3* routine assessment of patient index data, *SJC28* swollen joint count of 28 joints, *VAS* visual analog scale Fig. 3Baseline and last follow-up prednisone dosage for patients on DR-prednisone with a follow-up visit, a subset of patients on DR-prednisone for ≥10 weeks, and a subset of patients on DR-prednisone for ≥10 weeks with \>60 min of morning stiffness at baseline. Data are summarized as the mean (SD). *MS* morning stiffness

Length of Treatment {#Sec10}
-------------------

Due to the nature of the study, patients were not required to attend visits at a defined time point or to remain on therapy for a set period of time to be included in analysis; therefore, the length of time between baseline and follow-up varied (range 0.43--18.71 weeks). To overcome this study limitation, post hoc analyses evaluated the change from baseline in those patients exposed to DR-prednisone treatment for a period of time more consistent with a controlled clinical trial. Patients completing ≥10 weeks of DR-prednisone treatment \[mean (SD), 13.16 (2.26) weeks\] had significant reductions in morning stiffness duration (−27.22% or −35.00 \[81.89\] min, which exceeds the minimum threshold for clinically important morning stiffness reduction \[[@CR9]\]). SJC28 (−36.50%), PhGA (−18.90%), DAS28-CRP (−17.57%) (Fig. [4](#Fig4){ref-type="fig"}), and TJC28 scores (−29.69%) also improved. The disease activity index scores were also significantly reduced \[CDAI: 27.08 (15.53) vs. 37.93 (17.69) at baseline; *n* = 20; *p* \< 0.01; SDAI: 28.44 (17.61) vs. 38.17 (18.43) at baseline; *n* = 17; *p* \< 0.01\]. The mean change in CDAI of −10.85 (12.35) exceeds the minimum threshold (7.3) for clinically important improvement in moderate disease activity \[[@CR13]\]. Approximately 30% of patients improved by one category in both CDAI and SDAI. The change in morning stiffness severity between baseline and follow-up was −11.89% but not significant (*p* = 0.22); similarly, RAPID3 scores decreased but were not statistically significant (*p* = 0.11). The prednisone dose decreased by 13% from baseline but was not statistically significantly different \[mean (SD), 5.31 (2.55) vs. 6.09 (3.44) mg at baseline\] (Fig. [3](#Fig3){ref-type="fig"}). Among patients treated for \<10 weeks (*n* = 27), only the improvement in the functional component of the Multidimensional Health Assessment Questionnaire was significant (−22.59%; *p* = 0.02).Fig. 4SJC28 (**a**), morning stiffness duration (**b**), PhGA of disease activity (**c**), and DAS28-CRP (**d**) for patients on DR-prednisone for ≥10 weeks. Data are summarized as the mean (standard deviation). *DAS28-CRP* disease activity score in 28 joints by C-reactive protein; *PhGA* physician global assessment; *RAPID3* routine assessment of patient index data; *SJC28* swollen joint count of 28 joints; *VAS* visual analog scale

Patients who received DR-prednisone for ≥10 weeks and had greater disease burden at entry (\>60 min of baseline morning stiffness) had significant reductions in morning stiffness severity (−20.84%), morning stiffness duration (−30.98%), PhGA (−21.47%), and SJC28 (−30.64%) (Fig. [5](#Fig5){ref-type="fig"}). CDAI scores were also significantly reduced \[mean (SD), 27.79 (16.36) vs. 35.83 (17.60) at baseline; *n* = 12; *p* = 0.01\]. DAS28-CRP scores decreased but were not significant \[mean (SD), 4.27 (1.71) vs. 4.74 (1.35) at baseline; *n* = 10; *p* = 0.11\]. The prednisone dose decreased by 15% from baseline over the study period, but this was not statistically significant \[mean (SD), 4.88 (1.82) vs. 5.75 (3.61) mg at baseline\] (Fig. [3](#Fig3){ref-type="fig"}). Post hoc analysis revealed that morning stiffness severity and duration improvements were moderately correlated (*R* ^2^ = 0.54); no other correlations were demonstrated.Fig. 5Morning stiffness severity (**a**), morning stiffness duration (**b**), PhGA of disease activity (**c**), DAS28-CRP (**d**), SJC28 (**e**), and RAPID3 (**f**) for patients on DR-prednisone for ≥10 weeks with \>60 min of morning stiffness at baseline. Data are summarized as the mean (standard deviation). *DAS28-CRP* disease activity score in 28 joints by C-reactive protein; *PhGA* physician global assessment; *RAPID3* routine assessment of patient index data; *SJC28* swollen joint count of 28 joints; *VAS* visual analog scale

Adverse Events {#Sec11}
--------------

Twelve adverse events (AEs) occurred in the study and are summarized in Table [2](#Tab2){ref-type="table"}. Six events were considered by the investigator to be related to DR-prednisone. Of these, one patient continued taking DR-prednisone, and DR-prednisone was discontinued in the remaining patients because of high blood pressure, elevated blood glucose, worsening of joint pain, insomnia, and the single serious AE of severe abdominal pain with hospitalization.Table 2Adverse eventsEvent termSeveritySerious?Relationship to DR-prednisoneAction takenOutcomeUrinary tract with bloody urineModerateNoNoNoneRecovered/resolvedAnimal biteMildNoNoNoneRecovered/resolvedLung infectionModerateNoNoNoneRecovered/resolvedAnkle painMildNoNoNoneRecovered/resolvedDiarrheaMildNoNoNoneUnknownHigh blood pressureMildNoYesDiscontinuedRecovered/resolvedElevated blood glucoseMildNoYesDiscontinuedRecovered/resolvedWorsening of joint painMildNoYesDiscontinuedRecovered/resolvedGeneral malaise leading to loss of appetiteModerateNoNoNoneRecovered/resolvedAbdominal painSevereYesYesDiscontinuedRecovered/resolvedAbdominal pain and nauseaModerateNoYesNoneRecovered/resolvedInsomniaModerateNoYesDiscontinuedRecovered/resolved

Discussion {#Sec12}
==========

Due to the circadian release of pro-inflammatory mediators, pain and stiffness arising from RA are most severe in the early morning hours, significantly reducing patients' quality of life \[[@CR10]\]. DR-prednisone has previously been shown to reduce morning stiffness in clinical trials \[[@CR5], [@CR6]\]; however, not all trials permitted changes in prednisone dosage in patients switching from IR- to DR-prednisone.

Patients with moderate-to-severe RA who switched from IR- to DR-prednisone in this practice-based study maintained or improved their outcomes across a variety of domains. The results were comparable to previous studies of IR- versus DR-prednisone \[[@CR6], [@CR8], [@CR9]\], showing improved morning symptoms, but added to those data in that several other disease measures were improved with a lower total daily dose. These findings mirror two previous studies in polymyalgia rheumatica (PMR). One showed a clear trend for improved short-term outcomes using DR-prednisone as compared to IR-prednisone \[[@CR11]\], and another showed that 7 mg of DR-prednisone given in the evening achieved a similar percentage reduction in mean duration of morning stiffness as achieved with twice the dose of prednisolone in the morning \[[@CR12]\].

In the overall intention-to-treat (follow-up) population, there were significant reductions in swollen joint counts and physician global assessment of disease activity, RAPID3 and DAS28-CRP. Of particular note, patients treated for ≥10 weeks had significant reductions in morning stiffness duration, swollen joint counts, DAS28-CRP, physician global assessment of disease activity scores, and SDAI as well as a statistically and clinically significant improvement in CDAI \[[@CR13]\], indicating that DR-prednisone improved multiple clinical outcomes compared with its IR baseline counterpart, at a lower dose.

It has been shown that morning stiffness severity is strongly correlated with the intensity of morning pain and, to a lesser extent, disease activity and pain on waking \[[@CR14]\]. We completed subgroup analyses intending to match the baseline population characteristics from the previously published trials of DR-prednisone \[[@CR5]--[@CR9]\], and these results indicated there was significant improvement in morning stiffness severity, morning stiffness duration, physician global assessment of disease activity, clinical disease activity index, and swollen joint counts among patients with an initially high disease burden (\>60 min of morning stiffness at baseline) who were treated with DR-prednisone for ≥10 weeks. These results differed from those patients treated less than 10 weeks, who had lower disease activity, where there was no difference in disease measures. This may indicate that patients with active disease as reflected by prolonged morning stiffness have the potential to benefit more from treatment with a lower dose of DR-prednisone compared with IR-prednisone, validating the benefit of chronotherapy.

Despite its benefits in rheumatoid arthritis, long-term treatment with high-dose prednisone (\>10 mg) is associated with an increase in AEs. One study demonstrated that, compared with former users, current corticosteroid users had increased mortality, work disability, and total joint replacement \[[@CR15]\]. Furthermore, a large observational study of glucocorticoid users and nonusers found an increased relative risk of cardiovascular events among patients receiving high-dose prednisone \[[@CR16]\]. Studies have previously shown dose-dependent linear and threshold increases in AEs from lower (\<5 mg) to higher doses (7.5--10 mg); therefore, any reduction in prednisone dosage is advantageous for patients \[[@CR17]--[@CR21]\]. In the current study, the treating physician was allowed to decrease the dose of DR-prednisone at any time. A statistically nonsignificant but potentially clinically relevant reduction of prednisone dose by almost 1 mg/day/patient was observed in all the cohorts. The reduction in total prednisone dose over the treatment period was comparable to the 18% reduction found in a previous analysis \[[@CR22]\]. The reduction in glucocorticoid burden seen in these analyses with DR-prednisone is notable given the maintenance or improvement in disease measures.

This study has limitations primarily attributable to its practice-based nature, including lack of blinding and differing evaluation and follow-up intervals. The length of time between baseline and follow-up measurements was not mandated, resulting in varying lengths of drug exposure between subjects. Subgroup analysis of those in the study for ≥10 weeks created a more homogeneous population in terms of length in study, but reduced the sample size and concomitantly statistical power. Additionally, the average baseline morning stiffness in the follow-up study population was approximately 40--50 min less than in previous studies \[[@CR5], [@CR6]\], indicating that these patients, despite having similar disease scores, had lower morning disease symptoms. Another limitation of the study is patient adherence to the prescribed DR-prednisone regimen was not verified.

Conclusions {#Sec13}
===========

Patients with moderate-to-severe RA who had been maintained on IR-prednisone chronically and were switched to DR-prednisone in this practice-based study maintained or improved outcomes across a variety of domains, particularly when treated for ≥10 weeks. There was a statistically non-significant but potentially clinically relevant reduction of prednisone dose by almost 1 mg/day/patient in the cohorts evaluated.

These findings suggest that patients with moderately to severely active RA who have been treated with low-dose IR-prednisone may benefit from switching to DR-prednisone at a lower dose.
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